Q5118 Injection., zirabev, 10 milligrams
Also known as: Zirabev injection, bevacizumab-bvzr
Injection of Zirabev, bevacizumab-bvzr biosimilar per 10 milligrams, a vascular endothelial growth factor inhibitor.
In Plain Language
anti-angiogenic cancer drug; tumor vessel blocker
Clinical Context
Used for metastatic cancers including colorectal, non-squamous lung, and ovarian malignancies.
RVU Information
CPT Q5118 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5118?
CPT Q5118 (Injection., zirabev, 10 milligrams) is a Q Codes code. Injection of Zirabev, bevacizumab-bvzr biosimilar per 10 milligrams, a vascular endothelial growth factor inhibitor.
Is Q5118 covered by insurance?
Q5118 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for metastatic cancers including colorectal, non-squamous lung, and ovarian malignancies.
When is CPT Q5118 used?
Used for metastatic cancers including colorectal, non-squamous lung, and ovarian malignancies.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.